Ads
related to: new prostate cancer medication- HCP Resources
Useful Resources about XTANDI® for
Your Office and Your Patients
- Mechanism of Disease
Disease Information & Implications
Of Treatment with XTANDI®
- Important Safety Info
Safety Profile & Adverse Reactions
For XTANDI® (enzalutamide).
- Treatment Guidelines
Review NCCN and AUA Guidelines That
Support the Use of XTANDI®.
- HCP Resources
gotoper.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. [2] [9] It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), [2] nonmetastatic castration-resistant prostate cancer, [2] and metastatic castration-sensitive prostate ...
Abiraterone acetate is used in combination with prednisone, a corticosteroid, as a treatment for mCRPC (previously called hormone-resistant or hormone-refractory prostate cancer). [2] [6] [5] [4] This is a form of prostate cancer that is not responding to first-line androgen deprivation therapy or treatment with androgen receptor antagonists.
Patients with advanced prostate cancer have a greater chance of survival if treated with a targeted cancer drug in addition to chemotherapy, according to a new study.
PROSTVAC is being developed in partnership with the National Cancer Institute under a formal Cooperative Research and Development Agreement and has been the subject of multiple ongoing and completed clinical studies, including the global Phase 3 PROSPECT study underway in patients with asymptomatic or minimally symptomatic metastatic prostate cancer (mCRPC). [2]
One out of every six men will be diagnosed with prostate cancer.-- American Cancer Society At some point, it's likely that all of us will know someone who has been diagnosed with prostate cancer ...
Apalutamide was first described in 2007, and was approved for the treatment of prostate cancer in February 2018. [ 8 ] [ 9 ] [ 10 ] [ 15 ] It is the first medication to be approved specifically for the treatment of non-metastatic castration-resistant prostate cancer.
Ads
related to: new prostate cancer medicationgotoper.com has been visited by 10K+ users in the past month